Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.58
CYTX's Cash to Debt is ranked higher than
52% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CYTX: 0.58 )
CYTX' s 10-Year Cash to Debt Range
Min: 0.17   Max: No Debt
Current: 0.58

Equity to Asset -0.15
CYTX's Equity to Asset is ranked lower than
51% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTX: -0.15 )
CYTX' s 10-Year Equity to Asset Range
Min: -1.1   Max: 0.94
Current: -0.15

-1.1
0.94
F-Score: 2
Z-Score: -13.03
M-Score: -3.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -427.00
CYTX's Operating margin (%) is ranked higher than
61% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CYTX: -427.00 )
CYTX' s 10-Year Operating margin (%) Range
Min: -3958.33   Max: -68.58
Current: -427

-3958.33
-68.58
Net-margin (%) -491.89
CYTX's Net-margin (%) is ranked higher than
59% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CYTX: -491.89 )
CYTX' s 10-Year Net-margin (%) Range
Min: -3620.2   Max: -30.65
Current: -491.89

-3620.2
-30.65
ROA (%) -97.95
CYTX's ROA (%) is ranked higher than
52% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CYTX: -97.95 )
CYTX' s 10-Year ROA (%) Range
Min: -138.62   Max: -7.8
Current: -97.95

-138.62
-7.8
ROC (Joel Greenblatt) (%) -2424.44
CYTX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CYTX: -2424.44 )
CYTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2460.14   Max: -173.31
Current: -2424.44

-2460.14
-173.31
Revenue Growth (3Y)(%) -22.00
CYTX's Revenue Growth (3Y)(%) is ranked higher than
65% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CYTX: -22.00 )
CYTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.2
Current: -22

0
97.2
EBITDA Growth (3Y)(%) -9.50
CYTX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CYTX: -9.50 )
CYTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.3   Max: 37.5
Current: -9.5

-27.3
37.5
EPS Growth (3Y)(%) -7.70
CYTX's EPS Growth (3Y)(%) is ranked higher than
75% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CYTX: -7.70 )
CYTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.5   Max: 102.7
Current: -7.7

-41.5
102.7
» CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CYTX Guru Trades in Q1 2014

Paul Tudor Jones 14,433 sh (+30.90%)
Jim Simons Sold Out
» More
Q2 2014

CYTX Guru Trades in Q2 2014

Paul Tudor Jones 14,633 sh (+1.39%)
» More
Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2014

CYTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.48
CYTX's P/S is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CYTX: 10.48 )
CYTX' s 10-Year P/S Range
Min: 3.7   Max: 43.94
Current: 10.48

3.7
43.94
Current Ratio 1.36
CYTX's Current Ratio is ranked higher than
53% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CYTX: 1.36 )
CYTX' s 10-Year Current Ratio Range
Min: 1.36   Max: 32.68
Current: 1.36

1.36
32.68
Quick Ratio 1.06
CYTX's Quick Ratio is ranked higher than
53% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CYTX: 1.06 )
CYTX' s 10-Year Quick Ratio Range
Min: 1.06   Max: 31.14
Current: 1.06

1.06
31.14
Days Inventory 552.61
CYTX's Days Inventory is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CYTX: 552.61 )
CYTX' s 10-Year Days Inventory Range
Min: 36.86   Max: 529.06
Current: 552.61

36.86
529.06
Days Sales Outstanding 59.72
CYTX's Days Sales Outstanding is ranked higher than
84% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CYTX: 59.72 )
CYTX' s 10-Year Days Sales Outstanding Range
Min: 4.15   Max: 124.26
Current: 59.72

4.15
124.26

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.80
CYTX's Price/Median PS Value is ranked higher than
91% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CYTX: 0.80 )
CYTX' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 1.71
Current: 0.8

0.41
1.71
Earnings Yield (Greenblatt) -27.80
CYTX's Earnings Yield (Greenblatt) is ranked lower than
60% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CYTX: -27.80 )
CYTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -56.3   Max: 0
Current: -27.8

-56.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XMPA.Germany,
Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
cooldecency99 note on CYTX May 01 2010 
creiter note on CYTX Jan 03 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Reports 2nd Quarter 2009 Financial Results Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 


More From Other Websites
Most active Nasdaq-traded stocks Apr 24 2015
Cytori Provides Twelve Month Data Update on Scleradec-I Trial Apr 23 2015
Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds... Apr 23 2015
Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds... Apr 23 2015
The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori... Apr 16 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 13 2015
Cytori Provides Twelve Month Data Update on Scleradec-I Trial Apr 13 2015
Cytori CEO Tries His Best to Spin Stem-Cell Company's Setbacks Apr 08 2015
What Maxim Thinks Of Cytori After Its Huge Week Apr 08 2015
Exclusive: Cytori Therapeutics CEO Talks About Two Major Announcements In Two Days Apr 07 2015
Cytori Therapeutics (CYTX) Jumps: Stock Rises 13.8% - Tale of the Tape Apr 07 2015
Cytori Granted Orphan Drug Status for Cellular Therapeutic in European Union Apr 07 2015
Cytori Granted Orphan Drug Status for Cellular Therapeutic in European Union Apr 07 2015
Cytori Therapeutics (CYTX) Stock Spikes Today on Chinese Approval of Regenerative Cell Technology Apr 06 2015
Cytori rises as its Celution System is approved in China Apr 06 2015
Cytori rises as its Celution System is approved in China Apr 06 2015
Cytori and Lorem Vascular Receive Regulatory Clearance in China Apr 06 2015
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 06 2015
Cytori and Lorem Vascular Receive Regulatory Clearance in China Apr 06 2015
Cytori and Lorem Vascular Receive Regulatory Clearance in China Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK